TumorSight Risk: MRI-Based AI Predicts Breast Cancer Recurrence

FDA cleared TumorSight Risk, the first MRI-derived AI software, which predicts 5- and 10-year breast cancer recurrence risk in HR+, HER2- stage I-IIIA patients using breast MRI, pathology, and clinical data.

• The software integrates breast MRI, pathology, and clinical data to provide personalized risk scores.
• It targets women with hormone receptor-positive, HER2-negative stage I-IIIA breast cancer.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.